Novel trisubstituted harmine derivatives with original in vitro anticancer activity

Journal of Medicinal Chemistry

Volumn 55, Issue 14, 2012, Pages 6489-6501

  Frédérick, Raphaël ^a   Bruyére, Céline ^b   Vancraeynest, Christelle ^a   Reniers, Jérémy ^a   Meinguet, Céline ^a   Pochet, Lionel ^a   Backlund, Anders ^c   Masereel, Bernard ^a   Kiss, Robert ^b   Wouters, Johan ^a  

^a University of Namur   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 2 (4 FLUOROBENZYL) 7 (3 FLUOROBENZYL)OXY 9 (3 FLUOROBENZYL) BETA CARBOLINE 2 IUM BROMIDE; 1 METHYL 2 BENZYL 7 BENZYLOXY 9 BENZYL BETA CARBOLIN 2 IUM BROMIDE; 1 METHYL 2 BENZYL 7 CYCLOHEXYLMETHYLOXY 9 CYCLOHEXYLMETHYL BETA CARBOLIN 2 IUM BROMIDE; ANTINEOPLASTIC AGENT; BETA CARBOLINE DERIVATIVE; HARMINE; INITIATION FACTOR 2ALPHA; MITOTEMPOL; NSC 176098; NSC 24030; NSC 267709; NSC 342443; NSC 58924; NSC 634791; NSC 644614; NSC 747162; PHYLLANTOSIDE; PROTEIN DYRK1A; PROTEIN KINASE; PROTEIN SYNTHESIS INHIBITOR; TUBULIN; UNCLASSIFIED DRUG; UNDULATONE;

ALGORITHM; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIPOPHILICITY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; HARMINE; HUMANS; INHIBITORY CONCENTRATION 50; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84864213567     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300542e     Document Type: Article

References (56)

1. Savage, P.; Stebbing, J.; Bower, M.; Crook, T. Why does cytotoxic chemotherapy cure only some cancers? Nat. Clin. Pract. Oncol. 2009, 6, 43-52
2. Wilson, T. R.; Johnston, P. G.; Longley, D. B. Anti-apoptotic mechanisms of drug resistance in cancer Curr. Cancer Drug Targets 2009, 9, 307-319
3. Wong, R. S. Apoptosis in cancer: from pathogenesis to treatment J. Exp. Clin. Cancer Res. 2011, 30, 87
4. Martinez-Rivera, M.; Siddik, Z. H. Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53 Biochem. Pharmacol. 2012, 83 (8) 1049-1062
5. Rosenzweig, S. A. Acquired resistance to drugs targeting receptor tyrosine kinases Biochem. Pharmacol. 2012, 83 (8) 1041-1048
6. Rodrigues, A. S.; Dinis, J.; Gromicho, M.; Martins, C.; Laires, A.; Rueff, J. Genomics and cancer drug resistance Curr. Pharm. Biotechnol. 2012, 13 (5) 651-673
7. Lefranc, F.; Brotchi, J.; Kiss, R. Possible future issues in the treatment of glioblastomas, with a special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis J. Clin. Oncol. 2005, 23, 2411-2422
8. D'Amico, T. A.; Harpole, D. H., Jr. Molecular biology of esophageal cancer Chest Surg. Clin. N. Am. 2000, 10, 451-469
9. Bruyére, C.; Lonez, C.; Duray, A.; Cludts, S.; Ruysschaert, J. M.; Saussez, S.; Yeaton, P.; Kiss, R.; Mijatovic, T. Considering temozolomide as a novel potential treatment for esophageal cancer Cancer 2011, 117, 2004-2016
10. Soengas, M. S.; Lowe, S. W. Apoptosis and melanoma chemoresistance Oncogene 2003, 22, 3138-3151
11. Wong, H. H.; Lemoine, N. R. Pancreatic cancer: molecular pathogenesis and new therapeutic targets Nat. Rev. Gastroenterol. Hepatol. 2009, 6, 412-422
12. Han, S.; Roman, J. Targeting apoptotic signaling pathways in human lung cancer Curr. Cancer Drug Targets 2010, 10, 566-574
13. Becker, W.; Sippl, W. Activation, regulation, and inhibition of DYRK1A FEBS J. 2011, 278, 246-256
14. Wegiel, J.; Gong, C. X.; Hwang, Y. W. The role of DYRK1A in neurodegenerative diseases FEBS J. 2011, 278, 236-245
15. Cao, R.; Chen, H.; Peng, W.; Ma, Y.; Hou, X.; Guan, H.; Liu, X.; Xu, A. Design, synthesis and in vitro and in vivo antitumor activities of novel beta-carboline derivatives Eur. J. Med. Chem. 2005, 40, 991-1001
16. Bain, J.; Plater, L.; Elliott, M.; Shapiro, N.; Hastie, C. J.; McLauchlan, H.; Klevernic, I.; Arthur, J. S.; Alessi, D. R.; Cohen, P. The selectivity of protein kinase inhibitors: a further update Biochem. J. 2007, 408, 297-315
17. Gockler, N.; Fofre, G.; Papadopoulos, C.; Soppa, U.; Tejedor, F. J.; Becker, W. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation FEBS J. 2009, 276, 6324-6337
18. Seifert, A.; Allan, L. A.; Clarke, P. R. DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine FEBS J. 2008, 275, 6268-6280
19. Laguna, A.; Aranda, S.; Barallobre, M. J.; Barhoum, R.; Fernandez, E.; Fotaki, V.; Delabar, J. M.; de la Luna, S.; de la Villa, P.; Arbones, M. L. The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development Dev. Cell 2008, 15, 841-853
20. De Wit, N. R.; Burtscher, H. J.; Weidle, U. H.; Ruiter, D. J.; van Muijen, G. N. Differentially expressed genes identified in human melanoma cell lines with different metastatic behavior using high density oligonucleotide arrays Melanoma Res. 2002, 12, 57-69
21. Ma, Y.; Wink, M. The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells Phytother. Res. 2010, 24, 146-149
22. Reniers, J.; Robert, S.; Frederick, R.; Masereel, B.; Vincent, S.; Wouters, J. Synthesis and evaluation of beta-carboline derivatives as potential monoamine oxidase inhibitors Bioorg. Med. Chem. 2011, 19, 134-144
23. Dumont, P.; Ingrassia, L.; Rouzeau, S.; Ribaucour, F.; Thomas, S.; Roland, I.; Darro, F.; Lefranc, F.; Kiss, R. The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts Neoplasia 2007, 9, 766-776
24. Mathieu, V.; De Néve, N.; Le Mercier, M.; Dewelle, J.; Gaussin, J. F.; Dehoux, M.; Kiss, R.; Lefranc, F. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model Neoplasia 2008, 10, 1383-1392
25. Ingrassia, L.; Lefranc, F.; Dewelle, J.; Pottier, L.; Mathieu, V.; Spiegl-Kreinecker, S.; Sauvage, S.; El Yazidi, M.; Dehoux, M.; Berger, W.; Van Quaquebeke, E.; Kiss, R. Structure-activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents J. Med. Chem. 2009, 52, 1100-1114
26. Lamoral-Theys, D.; Andolfi, A.; Van Goietsenoven, G.; Cimmino, A.; Le Calvé, B.; Wauthoz, N.; Mégalizzi, V.; Gras, T.; Bruyére, C.; Dubois, J.; Mathieu, V.; Kornienko, A.; Kiss, R.; Evidente, A. Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight J. Med. Chem. 2009, 52, 6244-6256
27. Delbrouck, C.; Doyen, I.; Belot, N.; Decaestecker, C.; Ghanooni, R.; de Lavareille, A.; Kaltner, H.; Choufani, G.; Danguy, A.; Vandenhoven, G.; Gabius, H. J.; Hasid, S.; Kiss, R. Galectin-1 is overexpressed in nasal polyps under budesonide and inhibits eosinophil migration Lab. Invest. 2002, 82, 147-158
28. Lefranc, F.; Mijatovic, T.; Mathieu, V.; Rorive, S.; Decaestecker, C.; Debeir, O.; Brotchi, J.; Van Ham, P.; Salmon, I.; Kiss, R. Characterization of gastrin-induced proangiogenic effects in vivo in orthotopic U373 experimental human glioblastomas and in vitro in human umbilical vein endothelial cells Clin. Cancer Res. 2004, 10, 8250-8265
29. Mathieu, V.; Pirker, C.; martin de Lasalle, E.; Vernier, M.; Mijatovic, T.; De Néve, N.; Gaussin, J. F.; Dehoux, M.; Lefranc, F.; Berger, W.; Kiss, R. The sodium pump alpha-1 subunit: a disease progression-related target for metastatic melanoma treatment J. Cell. Mol. Med. 2009, 13, 3960-3972
30. Van Goietsenoven, G.; Hutton, J.; Becker, J. P.; Lallemand, B.; Robert, F.; Lefranc, F.; Pirker, C.; Vandenbussche, G.; Van Antwerpen, P.; Evidente, A.; Berger, W.; Prévost, M.; Pelletier, J.; Kiss, R.; Kinzy, T. G.; Kornienko, A.; Mathieu, V. Targeting of eEF1A with Anaryllidaceae isocarbostyrils as a strategy to combat melanomas FASEB J. 2010, 24, 4575-4584
31. Branle, F.; Lefranc, F.; Camby, I.; Jeuken, J.; Geurts-Moespot, A.; Sprenger, S.; Sweep, F.; Kiss, R.; Salmon, I. Evaluation of the efficiency of chemotherapy in in vivo orthtopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy Cancer 2002, 95, 641-655
32. Developmental Therapeutic Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, U.S. http://dtp.cancer.gov.
33. Larsson, J.; Gottfries, J.; Bohlin, L.; Backlund, A. Expanding the ChemGPS chemical space with natural products J. Nat. Prod. 2005, 68, 985-991
34. Larsson, J.; Gottfries, J.; Muresan, S.; Backlund, A. ChemGPS-NP: tuned for navigation in biologically relevant chemical space J. Nat. Prod. 2007, 70, 789-794
35. Web: chemical space navigation online J. Comput.-Aided Mol. Des. 2009, 23, 253-259
36. Belot, N.; Rorive, S.; Doyen, I.; Lefranc, F.; Bruyneel, E.; Dedecker, R.; Micik, S.; Brotchi, J.; Decaestecker, C.; Salmon, I.; Kiss, R.; Camby, I. Molecular characterization of cell substratum attachments in human glial tumors relates to prognostic features Glia 2001, 36, 375-390
37. Sivasankaran, B.; Degen, M.; Ghaffari, A.; Hegi, M. E.; Hamou, M. F.; Ionescu, M. C.; Zweifel, C.; Tolnay, M.; Wasner, M.; Mergenthaler, S.; Miserez, A. R.; Kiss, R.; Lino, M. M.; Merlo, A.; Chiquet-Ehrismann, R.; Boulay, J. L. Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas Cancer Res. 2009, 69, 458-465
38. Yang, B. F.; Xiao, C.; Roa, W. H.; Krammer, P. H.; Hao, C. Calcium/calmodulin-dependent protein kinase II regulation of c-FLIP expression and phosphorylation in modulation of Fas-mediated signaling in malignant glioma cells J. Biol. Chem. 2003, 278, 7043-7050
39. Takai, N.; Ueda, T.; Nasu, K.; Yamashita, S.; Toyofuku, M.; Narahara, H. Targeting calcium/calmodulin-dependence kinase I and II as a potential anti-proliferation remedy for endometrial carcinomas Cancer Lett. 2009, 277, 235-243
40. Han, Y. J.; Ma, S. F.; Yourek, G.; Park, Y. D.; Garcia, J. G. A transcribed pseudogene of MYLK promotes cell proliferation FASEB J. 2011, 25, 2305-2312
41. Horbelt, D.; Denkis, A.; Knaus, P. A portrait of transforming growth factor beta superfamily signaling: background matters Int. J. Biochem. Cell Biol. 2012, 44, 469-474
42. Wang, P.; Yu, J.; Yin, Q.; Li, W.; Ren, X.; Hao, X. Rosiglitazone suppresses glioma cell growth and cell cycle by blocking the transforming growth factor-beta mediated pathway. Neurochem. Res. [Online early access]. DOI: 10.1007/s11064-012-0828-8. Published Online: 2012.
43. Zoubeidi, A.; Rocha, J.; Zouanat, F. Z.; Hamel, L.; Scarlata, E.; Aprikian, A. G.; Chevalier, S. The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth Mol. Cancer Res. 2009, 7, 142-155
44. Wang, S. Y.; Li, F. F.; Zheng, H.; Yu, K. K.; Ni, F.; Yang, X. M.; Qu, C. K.; Li, J. Rapid induction and activation of Tec tyrosine kinase in liver regeneration J. Gastroenterol. Hepatol. 2006, 21, 668-673
45. Feng, X.; Lu, X.; Man, X.; Zhou, W.; Jiang, L. Q.; Knyazev, P.; Lei, L.; Huang, Q.; Ullrich, A.; Zhang, Z.; Chen, Z. Overexpression of Csk-binding protein contributes to renal cell carcinogenesis Oncogene 2009, 28, 3320-3331
46. Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm J. Natl. Cancer Inst. 1989, 81, 1088-1092
47. Chan, J.; Khan, S. N.; Harvey, I.; Merrick, W.; Pelletier, J. Eukaryotic protein synthesis inhibitors identified by comparison of cytotoxicity profiles RNA 2004, 10, 528-543
48. Gharehbaghi, K.; Paul, K.; Kelley, J. J.; Barchi, J. J., Jr.; Marquez, V. E.; Cooney, D. A.; Monks, A.; Scudiero, D.; Kohn, K.; Jayaram, H. N. Cytotoxicity and characterization of an active metabolite of benzamide ribosode: a novel inhibitor of IMP dehydrogenase J. Cancer 1994, 56, 892-899
49. Cleaveland, E. S.; Monks, A.; Vaigro-Wolff, A.; Zaharevitz, D. W.; Paull, K.; Ardalan, K.; Cooney, D. A.; Ford, H., Jr. Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the COMPARE program Biochem. Pharmacol. 1995, 49, 947-954
50. Kohlhagen, G.; Paull, K.; Cushman, M.; Nagafuji, P.; Pommier, Y. Protein-linked DNA strand breaks induced by NSC314622: a novel non-camptothecin topoisomerase I poison Mol. Pharmacol. 1998, 54, 50-58
51. Zaharevitz, D. W.; Gussio, R.; Loest, M.; Senderowicz, A. M.; Lahusen, T.; Kunick, C.; Meijer, L.; Sausville, E. A. Discovery and initial characterization of the paullones: a novel class of small-molecule inhibitors of cyclin-dependent kinases Cancer Res. 1999, 59, 2566-2569
52. Kupchan, S. M.; LaVoie, E. J.; Branfman, A. R.; Fei, B. Y.; Bright, W. M.; Bryan, R. F. Phyllantocin, a novel bisabolane aglycone from the antileukemic glycoside, phyllantoside J. Am. Chem. Soc. 1977, 99, 3199-3201
53. Choi, H. C.; Song, P.; Xie, Z.; Wu, Y.; Xu, J.; Zhang, M.; Dong, Y.; Wang, S.; Lau, K.; Zou, M. H. Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo J. Biol. Chem. 2008, 283, 20186-20197
54. Lamoral-Theys, D.; Pottier, L.; Kerff, F.; Dufrasne, F.; Proutiére, F.; Wauthoz, N.; Neven, P.; Ingrassia, L.; Van Antwerpen, P.; Lefranc, F.; Gelbcke, M.; Pirotte, B.; Kraus, J. L.; Néve, J.; Kornienko, A.; Kiss, R.; Dubois, J. Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli Bioorg. Med. Chem. 2010, 18, 3823-3833
55. 2+ release J. Cell. Mol. Med. 2012, 16, 1421-1434
56. Dolusic, E.; Larrieu, P.; Moineaux, L.; Stroobant, V.; Pilotte, L.; Colau, D.; Pochet, L.; Van den Eynde, B.; Masereel, B.; Wouters, J.; Frederick, R. Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as potential anticancer immunomodulators J. Med. Chem. 2011, 54 (15) 5320-5334